Combination temozolomide and irinotecan was called an “excellent option” for patients with Ewing sarcoma who have lung- or bone-only metastases, by investigators at the 2016 annual meeting of the American Society of Clinical Oncology (abstract 11033). The drug combination was also found to be particularly effective in adults and in patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0.
The group of Italian and British investigators noted previous